- Home
- CLPS vs TPST Comparison
CLPS vs TPST Comparison
Compare CLPS & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLPS
- TPST
- Stock Information
- Founded
- CLPS 2005
- TPST 2011
- Country
- CLPS Hong Kong
- TPST United States
- Employees
- CLPS N/A
- TPST N/A
- Industry
- CLPS Computer Software: Prepackaged Software
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- CLPS Technology
- TPST Health Care
- Exchange
- CLPS Nasdaq
- TPST Nasdaq
- Market Cap
- CLPS 25.6M
- TPST 33.0M
- IPO Year
- CLPS 2018
- TPST N/A
- Fundamental
- Price
- CLPS $1.00
- TPST $6.66
- Analyst Decision
- CLPS
- TPST Hold
- Analyst Count
- CLPS 0
- TPST 3
- Target Price
- CLPS N/A
- TPST $30.00
- AVG Volume (30 Days)
- CLPS 9.8K
- TPST 72.4K
- Earning Date
- CLPS 03-05-2025
- TPST 08-07-2025
- Dividend Yield
- CLPS 13.00%
- TPST N/A
- EPS Growth
- CLPS N/A
- TPST N/A
- EPS
- CLPS N/A
- TPST N/A
- Revenue
- CLPS $153,816,045.00
- TPST N/A
- Revenue This Year
- CLPS N/A
- TPST N/A
- Revenue Next Year
- CLPS N/A
- TPST N/A
- P/E Ratio
- CLPS N/A
- TPST N/A
- Revenue Growth
- CLPS 5.81
- TPST N/A
- 52 Week Low
- CLPS $0.68
- TPST $5.35
- 52 Week High
- CLPS $1.70
- TPST $29.38
- Technical
- Relative Strength Index (RSI)
- CLPS 57.62
- TPST 42.36
- Support Level
- CLPS $0.94
- TPST $6.57
- Resistance Level
- CLPS $1.03
- TPST $7.05
- Average True Range (ATR)
- CLPS 0.04
- TPST 0.26
- MACD
- CLPS 0.01
- TPST -0.06
- Stochastic Oscillator
- CLPS 82.70
- TPST 8.45
About CLPS CLPS Incorporation
CLPS Inc is a holding company. The company through its subsidiaries provides information technology consulting and solutions institutions in the banking, insurance, and financial sectors, both in China and globally. Its products are Risk Control Platform, Transaction Acquiring Platform, Debt Collection Platform, Virtual Bank Training Platform, Credit Card System, and other related products. The company generates its revenue from IT consulting services, Customized IT solution services, and others. Generating the majority of its revenue from the IT consulting service.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.